Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Summary

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

Timeline

Start

2019-06-27

Primary completion

2020-12-01

Completion

2021-01-29

Outcome

Missed primary endpoint

Stopped (Business): “for business reasons”

registry analysis (superiority test); Azeliragon vs Placebo; p = 0.2057; Mixed Models Analysis NCT03980730 ↗

release “The Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective” vtvtherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azeliragon	Small molecule	5 mg	Oral

Indications